Hangzhou 1gene Technology Co., Ltd. announced a private placement of common shares for gross proceeds of CNY 30 million on November 7, 2022. The transaction will include participation from new investor, ChengDa Pharmaceuticals Co., Ltd. which will acquire 12% equity stake in the company. After this capital increase, the registered capital of company will be increased from CNY 20,393,939 to CNY 23,174,931.